TSB Therapeutics, the holding company of Brii Bio, and Sinopharm have entered into a strategic collaboration to commercialize Brii Bio’s long-acting neutralizing monoclonal antibody (mAb) drug, a combination of amubarvimab and romlusevimab to treat Covid-19, in China
On December 8, 2021, the National Medical Products Administration (NMPA) of China approved the amubarvimab/romlusevimab combination for the treatment in adults and pediatric patients with mild and normal type of COVID-19 at high risk for progression to severe disease, including hospitalization or death. The indication of pediatric patients is under a conditional approval. On March 15, 2022, the National Health Commission of China added the amubarvimab/romlusevimab combination to its COVID-19 Diagnosis and Treatment Guidelines for the treatment of COVID-19.
Rogers Luo, President and General Manager of Brii Bio, and Chief Executive Officer of TSB Therapeutics, said:
The pandemic continues to affect the health of communities worldwide and most recently aggressively impacting China. As a biotechnology company with the mission of tackling the major public health challenges, we are duty-bound to support the pandemic prevention and control. We are pleased to partner with Sinopharm Holding, a leading state-owned pharmaceutical distribution company in China. We believe that with their advanced distribution channels and strong channel management ability, we are able to accelerate the accessibility of our amubarvimab/romlusevimab combination to help more COVID-19 patients in China.
Yong Liu, President and Deputy Secretary of the Party Committee of Sinopharm Holding, said:
It has been three years since the outbreak of the pandemic. We have been expecting treatment solutions to be available in addition to the COVID-19 vaccines. As a central pharmaceutical stockpiling company, Sinopharm Holding is committed to ensuring the drug supply for our country and people. The strategic partnership with Brii Bio marks essential public health cooperation between a commercial enterprise and an industrial enterprise. We will leverage our strong distribution network in cooperation with our provincial subsidiaries and our global procurement and supply chain centers, to provide a comprehensive strategy, including drug stockpiling, commercialization, and innovation services, thereby improving the accessibility of Brii Bio’s self-developed COVID-19 antibody therapy and benefiting more patients.
With the recognition of the national healthcare authorities and clinical experts for the amubarvimab/romlusevimab combination, as of March 29, 2022, TSB Therapeutics has received purchase intention and stockpiling requests from nearly 20 provincial Health Commissions, over 100 healthcare institutions and commercial organizations. The Company is rapidly preparing production and supply to provide the combination therapy to patients in need as soon as possible.
